AKT

[Cell Death & Disease] USP35 promoted the growth of ER+ breast cancer in vitro and in vivo, and reduced the sensitivity of ER+ breast cancer cells to endocrine therapies such as tamoxifen and fulvestrant.

[Cell Death & Disease] Investigators identified Insulin gene enhancer binding protein 1 (ISL1) as an oncogene in neuroblastoma (NB). ISL1 is preferentially upregulated in NB tissues compared with normal tissues.

[Nature Communications] Scientists hypothesized that targeted hyperactivation of the phosphatidylinositol-3-phosphate/AKT (PI3K/AKT)-signaling pathway may have been leveraged to trigger chronic lymphocytic leukemia cell death.

[Cancer Gene Therapy] The authors reported that cabozantinib could promote differentiation in erythroid leukemia cells and found that K562 erythroid leukemia cells treated with 1 μM cabozantinib for 72 hours underwent erythroid lineage differentiation.

[Blood] Investigators discovered that FLT3-ITD, one of the most frequent mutations in acute myeloid leukemia, was S-palmitoylated by the ZDHHC6 palmitoyl acyltransferase. Disruption of palmitoylation redirected FLT3-ITD to the plasma membrane and rewired its downstream signaling by activating AKT and ERK pathways in addition to STAT5.

[Cell Death Discovery] Scientists found that lenalidomide, a representative of immunomodulatory drugs (IMiDs), specifically induced accumulation of Ik6 with the disappearance of functional isoforms within 24 hours in Ik6-positive Philadelphia chromosome-positive acute lymphoblastic leukemia cells in a neddylation-dependent manner.